当前位置：
X-MOL 学术
›
ACS Pharmacol. Transl. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19
ACS Pharmacology & Translational Science Pub Date : 2020-08-27 , DOI: 10.1021/acsptsci.0c00071 Dhanusha A. Nalawansha 1 , Kusal T. G. Samarasinghe 1
ACS Pharmacology & Translational Science Pub Date : 2020-08-27 , DOI: 10.1021/acsptsci.0c00071 Dhanusha A. Nalawansha 1 , Kusal T. G. Samarasinghe 1
Affiliation
|
Coronavirus is one of the causative agents for multiple human respiratory illnesses. A novel coronavirus, similar to the one that caused severe acute respiratory syndrome (SARS) in 2003, was identified as the cause of the current pandemic of coronavirus disease (COVID-19), which was first reported in late December 2019 in Wuhan, China. Since then, this novel coronavirus has spread across the globe, with most identified COVID-19 cases and fatalities occurring in the United States. In this Perspective, we discuss coronavirus pathogenicity, conventional antiviral therapies, prophylactic strategies, and novel treatment strategies for COVID-19. We highlight the application of CRISPR technology as an emerging pan-antiviral therapy. We also discuss the challenges of in vivo delivery of CRISPR components and propose novel approaches to achieve selective delivery exclusively into SARS-CoV-2-infected cells with high efficiency by hijacking the surface proteins of SARS-CoV-2.
更新日期：2020-10-11
京公网安备 11010802027423号